Long-term follow-up of seven patients with ophthalmopathy not associated with thyroid autoimmunity: Heterogeneity of autoimmune ophthalmopathy

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1063-1071

  McCorquodale, Tom ^a   Lahooti, Hooshang ^a   Gopinath, Bamini ^b   Wall, Jack R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Calsequestrin; Collagen XIII; Euthyroid Graves' disease; Ophthalmopathy; Thyroid eye disease

Indexed keywords

AZATHIOPRINE; CALSEQUESTRIN; COLLAGEN TYPE 13; EYE DROPS; PREDNISOLONE; STEROID; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; MALE; OUTCOME ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION;

EID: 84865642119     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S30704     Document Type: Article

References (30)

1. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12:855-860.
2. Burch HB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747-793.
3. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284-290.
4. Gopinath B, Tani J, Bao N, Wall JR. Eye muscle and collagen XIII antibodies and eye signs in patients with transient and chronic thyroiditis. Thyroid. 2007;17:1-7.
5. Tjiang H, Lahooti H, McCorquodale T, Parmar KR, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto's thyroiditis. Thyroid. 2010;20:287-290.
6. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-3470.
7. Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42:565-569.
8. Weetman AP. Graves' disease. N Engl J Med. 2000;343:1236-1248.
9. Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab. 2003; 88:1939-1946.
10. Wall JR. The TSH-receptor and thyroid-associated ophthalmopathy: A convenient hypothesis with too many exceptions to be true. Int J Endocrinol Metab. 2007;2:49-51.
11. Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Biophys Mol Biol. 2004;85:33-69.
12. Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T. Type XIII collagen is identified as a plasma membrane protein. J Biol Chem. 1998;273:15590-15597.
13. Gopinath B, Musselman R, Beard N, Tani J, Adams C, Wall JR. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are sensitive and specific markers of ocular myopathy in patients with Graves' disease. Clin Exp Immunol. 2006;145:56-62.
14. Gopinath B, Musselman R, Adams C, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: Correlation with clinical features. Thyroid. 2006;16:967-974.
15. De Bellis A, Sansone D, Coronella C, et al. Serum antibodies to collagen XIII: A further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005;62:24-29.
16. Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg. 1993;9:77-82.
17. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol. 1989;73:639-644.
18. Werner SC. Classification of the eye changes of Graves' disease. Am J Ophthalmol. 1969;68:646-648.
19. Wall JR, Kiljanski J, Nebes V, Stachura I, Kennerdell JS. Should Graves' disease be considered a collagen disorder of the thyroid, skeletal muscle and connective tissue? Hor Metab Res. 1995;27:528-532.
20. Wall JR. Extra thyroidal manifestations of Graves' disease. J Clin Endocrinol Metab. 1996;80:3427-3429.
21. Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990;70:89-94.
22. Medeiros-Neto G, Zhang ZG, Lima N, et al. Immunologically mediated cytotoxicity against human eye muscle and thyroid cells in euthyroid and thyrotoxic Graves' ophthalmopathy. Autoimmunity. 1991;9:293-300.
23. Hansen C, Fraiture B, Rouhi R, Otto E, Förster G, Kahaly G. HPLC glycosaminoglycan analysis in patients with Graves' disease. Clin Sci (Lond). 1997;92:511-517.
24. Kahaly G, Stover C, Otto E, Beyer J, Schuler M. Glycosaminoglycans in thyroid-associated ophthalmopathy. Autoimmunity. 1992;13:81-88.
25. Kim WB, Chung HK, Park YJ, et al. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease. Thyroid. 2000;10:579-586.
26. Tani J, Wall JR. Analysis: Can the development of thyroid-associated ophthalmopathy be explained by autoimmunity against eye muscle antigens? Canad Med Assoc. 2006;17:239-241.
27. Tani J, Gopinath B, Nuygen B, Wall JR. Immunological mechanisms for the eye muscle and orbital connective tissue reactions of thyroid-associated ophthalmopathy. Expert Rev Clin Immunol. 2007;3:299-311.
28. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci U S A. 2001;98:12062-12067.
29. Huang D, Xu N, Song Y, Wang P, Yang H. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):619-625.
30. Khalilzadeh O, Anvari M, Esteghamati A, et al. Genetic susceptibility to Graves' ophthalmopathy: The role of polymorphisms in anti-inflammatory cytokine genes. Ophthalmic Genet. 2010;31:215-220.